Achaogen Inc (AKAO, Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Achaogen Inc is a biopharmaceutical company committed to the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections. Achaogen Inc has a market cap of $27.590 million; its shares were traded at around $0.44 with and P/S ratio of 2.30.
For the last quarter Achaogen Inc reported a revenue of $2.03 million, compared with the revenue of $1.87 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $8.73 million, a decrease of 21.9% from the previous year. For the last five years Achaogen Inc had an average revenue decline of 13.4% a year.
The reported loss per diluted share was $4.25 for the year, compared with the loss per share of $1.49 in the previous year. The Achaogen Inc had an operating margin of -1897.88%, compared with the operating margin of -1130.43% a year before. The 10-year historical median operating margin of Achaogen Inc is -99.08%. The profitability rank of the company is 1 (out of 10).
At the end of the fiscal year, Achaogen Inc has the cash and cash equivalents of $31.0 million, compared with $145.2 million in the previous year. The company had no long term debt, compared with $9.46 million in the previous year. Achaogen Inc has a financial strength rank of 2 (out of 10).
At the current stock price of $0.44, Achaogen Inc is traded at 54.2% discount to its historical median P/S valuation band of $0.96. The P/S ratio of the stock is 2.30, while the historical median P/S ratio is 5.03. The stock lost 96.48% during the past 12 months.
Directors and Officers Recent Trades:
- 10% Owner Robert W Duggan sold 1,277,888 shares of AKAO stock on 03/20/2019 at the average price of $0.54.
- 10% Owner Robert W Duggan sold 2,354,007 shares of AKAO stock on 03/13/2019 at the average price of $0.6.
For the complete 20-year historical financial data of AKAO, click here.
